GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eledon Pharmaceuticals Inc (FRA:2TK) » Definitions » Cyclically Adjusted PB Ratio

Eledon Pharmaceuticals (FRA:2TK) Cyclically Adjusted PB Ratio : 0.01 (As of Sep. 21, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Eledon Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2024-09-21), Eledon Pharmaceuticals's current share price is €2.16. Eledon Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2024 was €155.65. Eledon Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 0.01.

The historical rank and industry rank for Eledon Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

FRA:2TK' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0.02
Current: 0.02

During the past years, Eledon Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 0.02. The lowest was 0.00. And the median was 0.00.

FRA:2TK's Cyclically Adjusted PB Ratio is ranked better than
99.83% of 606 companies
in the Biotechnology industry
Industry Median: 1.605 vs FRA:2TK: 0.02

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Eledon Pharmaceuticals's adjusted book value per share data for the three months ended in Jun. 2024 was €-0.205. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €155.65 for the trailing ten years ended in Jun. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Eledon Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Eledon Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eledon Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Eledon Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 0.02 0.01

Eledon Pharmaceuticals Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 0.02

Competitive Comparison of Eledon Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Eledon Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eledon Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eledon Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Eledon Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Eledon Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Eledon Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=2.16/155.65
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eledon Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2024 is calculated as:

For example, Eledon Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Jun. 2024 was:

Adj_Book=Book Value per Share/CPI of Jun. 2024 (Change)*Current CPI (Jun. 2024)
=-0.205/132.5538*132.5538
=-0.205

Current CPI (Jun. 2024) = 132.5538.

Eledon Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201409 584.811 100.428 771.887
201412 607.549 99.070 812.892
201503 607.508 99.621 808.338
201506 531.158 100.684 699.288
201509 459.588 100.392 606.826
201512 406.215 99.792 539.574
201603 330.397 100.470 435.903
201606 247.688 101.688 322.869
201609 192.895 101.861 251.018
201612 -20.428 101.863 -26.583
201703 156.304 102.862 201.422
201706 54.076 103.349 69.357
201709 44.847 104.136 57.086
201712 41.609 104.011 53.027
201803 37.706 105.290 47.470
201806 35.236 106.317 43.932
201809 30.002 106.507 37.339
201812 24.334 105.998 30.430
201903 16.742 107.251 20.692
201906 19.683 108.070 24.142
201909 16.836 108.329 20.601
201912 11.825 108.420 14.457
202003 11.906 108.902 14.492
202006 7.717 108.767 9.405
202009 14.325 109.815 17.291
202012 10.334 109.897 12.465
202103 10.796 111.754 12.805
202106 10.357 114.631 11.976
202109 10.145 115.734 11.619
202112 10.145 117.630 11.432
202203 10.318 121.301 11.275
202206 10.272 125.017 10.891
202209 10.359 125.227 10.965
202212 5.768 125.222 6.106
202303 5.071 127.348 5.278
202306 4.003 128.729 4.122
202309 3.635 129.860 3.710
202312 0.273 129.419 0.280
202403 2.774 131.776 2.790
202406 -0.205 132.554 -0.205

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Eledon Pharmaceuticals  (FRA:2TK) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Eledon Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Eledon Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Eledon Pharmaceuticals Business Description

Traded in Other Exchanges
Address
19900 MacArthur Boulevard, Suite 550, Irvine, CA, USA, 92612
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's lead compound in development is AT-1501 which is the next generation anti-CD40L antibody.

Eledon Pharmaceuticals Headlines

No Headlines